By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Telecommute Arrangement: What's Pivotal for Your Efficiency? - 2Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- 3South America's Memorable Destinations: A Movement Guide
- 4Trump signs bill allowing whole milk to return to school lunches
- 5US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- Mating injuries may lead scientists to identify dinosaurs’ sex
- German gas price bill signed into law, but consumers not impressed
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Intriguing Social Unesco World Legacy Locales All over The Planet
- Partner of crime boss Steven Lyons arrested in Dubai
- Step by step instructions to Protect Your Speculations with Cd Rates
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- Pick Your #1 game to observe
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
